B BioMarin Pharmaceuticals
| Market Cap | $10.67B |
| P/E Ratio | 30.83 |
| Forward P/E | 8.24 |
| Dividend Yield | — |
| Beta | 0.29 |
| 52W Range | $51.46 - $67.48 |
| # Hedge Funds | 2 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 2 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 0.95% | $358.77M | 6,036,936 | Reduce 27.46% |
| Dodge & Cox Dodge & Cox | 0.47% | $866.04M | 14,572,384 | Reduce 0.78% |
Insider Trading
| Insider Name of the company insider who made the trade 3 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Guyer Charles GregEVP, Chief Technical Officer | Sale | 16,486 | $60.46 | $996.74K | 11 Mar 2026 | 11 Mar 2026 |
| Friberg Gregory REVP, Chief R&D Officer | Sale | 6,326 | $60.38 | $381.94K | 26 Feb 2026 | 26 Feb 2026 |
| Davis George EricEVP, Chief Legal Officer | Sale | 26,061 | $61.36 | $1.60M | 26 Feb 2026 | 26 Feb 2026 |
Frequently Asked Questions
What is BMRN stock price today?
BioMarin Pharmaceuticals (BMRN) is currently trading at $55.50. The stock has a 52-week range of $51.46 to $67.48 and a market capitalization of $10.67B.
Is BMRN a good stock to buy in 2026?
BioMarin Pharmaceuticals has a P/E ratio of 30.8 (forward P/E: 8.2), a dividend yield of none, and 1-year performance of -17.8%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling BMRN stock?
There have been 3 insider transactions for BMRN in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has BMRN stock performed over the past year?
BioMarin Pharmaceuticals (BMRN) has returned -17.8% over the past 12 months. The stock traded between $51.46 and $67.48 during this period, and is currently at $55.50.
Which hedge funds own BMRN (BioMarin Pharmaceuticals)?
2 tracked hedge funds currently hold BMRN in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is BMRN's market cap and valuation?
BioMarin Pharmaceuticals (BMRN) has a market capitalization of $10.67B. The trailing P/E ratio is 30.8 and forward P/E is 8.2. The stock is classified in the Healthcare sector.
What is BMRN's revenue and profitability?
BioMarin Pharmaceuticals reported revenue of $3.22B with net income of $348.90M and a profit margin of 0.11%. The stock has a beta of 0.29.
What sector is BMRN in and who are its biggest institutional holders?
BioMarin Pharmaceuticals (BMRN) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.